RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Synucleinopathies are age-related neurological disorders characterized by the progressive deposition of α-synuclein (α-syn) aggregates and include Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Although cell-to-cell α-syn transmission is thought to play a key role in the spread of α-syn pathology, the detailed mechanism is still unknown. Neuroinflammation is another key pathological feature of synucleinopathies. Previous studies have identified several immune receptors that mediate neuroinflammation in synucleinopathies, such as Toll-like receptor 2 (TLR2). However, the species of α-syn aggregates varies from study to study, and how different α-syn aggregate species interact with innate immune receptors has yet to be addressed. Therefore, we investigated whether innate immune receptors can facilitate the uptake of different species of α-syn aggregates. Here, we examined whether stimulation of TLRs could modulate the cellular uptake and degradation of α-syn fibrils despite a lack of direct interaction. We observed that stimulation of TLR2 in vitro accelerated α-syn fibril uptake in neurons and glia while delaying the degradation of α-syn in neurons and astrocytes. Internalized α-syn was rapidly degraded in microglia regardless of whether TLR2 was stimulated. However, cellular α-syn uptake and degradation kinetics were not altered by TLR4 stimulation. In addition, upregulation of TLR2 expression in a synucleinopathy mouse model increased the density of Lewy-body-like inclusions and induced morphological changes in microglia. Together, these results suggest that cell type-specific modulation of TLR2 may be a multifaceted and promising therapeutic strategy for synucleinopathies; inhibition of neuronal and astroglial TLR2 decreases pathogenic α-syn transmission, but activation of microglial TLR2 enhances microglial extracellular α-syn clearance.

참고문헌 (Reference)

1 김창연, "b1-integrin-dependent migration of microglia response to neuron-released a-synuclein" 생화학분자생물학회 46 : 1-10, 2014

2 McCann, H., "alphaSynucleinopathy phenotypes" 20 : S62-S67, 2014

3 Hansen, C., "alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells" 121 : 715-725, 2011

4 Kakuda, K., "Ultrasonication-based rapid amplification of alpha-synuclein aggregates in cerebrospinal fluid" 9 : 6001-, 2019

5 Manne, S., "Ultrasensitive detection of aggregated alpha-synuclein in glial cells, human cerebrospinal fluid, and brain tissue using the RT-QuIC assay : new high-throughput neuroimmune biomarker assay for Parkinsonian disorders" 14 : 423-435, 2019

6 Stefanova, N., "Toll-like receptor 4 promotes alpha-synuclein clearance and survival of nigral dopaminergic neurons" 179 : 954-963, 2011

7 Fellner, L., "Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia" 61 : 349-360, 2013

8 Dzamko, N., "Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology" 133 : 303-319, 2017

9 Van der Perren, A., "The structural differences between patient-derived alpha-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies" 139 : 977-1000, 2020

10 Lashuel, H. A., "The many faces of alphasynuclein: from structure and toxicity to therapeutic target" 14 : 38-48, 2013